Shares of Bluebird Bio Inc. (NASDAQ:BLUE) dropped 2.2% during trading on Thursday . The company traded as low as $48.54 and last traded at $49.13, with a volume of 876,687 shares. The stock had previously closed at $50.26.

A number of equities analysts recently issued reports on the company. Piper Jaffray Cos. reissued a “buy” rating and set a $117.00 price target on shares of Bluebird Bio in a report on Wednesday, May 11th. Janney Montgomery Scott reissued a “buy” rating and set a $91.00 price target on shares of Bluebird Bio in a report on Tuesday, May 10th. Leerink Swann reissued a “buy” rating on shares of Bluebird Bio in a report on Monday, June 13th. Jefferies Group reissued a “buy” rating and set a $80.00 price target (down previously from $84.00) on shares of Bluebird Bio in a report on Saturday, May 7th. Finally, BTIG Research reissued a “buy” rating and set a $72.00 price target on shares of Bluebird Bio in a report on Saturday, May 7th. Six analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Bluebird Bio currently has an average rating of “Buy” and a consensus target price of $82.50.

The company’s market capitalization is $1.90 billion. The stock has a 50-day moving average of $52.63 and a 200 day moving average of $47.03.

Bluebird Bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.15. The business had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $2.01 million. The company’s revenue was down 68.6% compared to the same quarter last year. During the same period last year, the business posted ($1.57) EPS. Analysts predict that Bluebird Bio Inc. will post ($6.14) earnings per share for the current fiscal year.

In other Bluebird Bio news, insider Eric Sullivan sold 2,912 shares of the company’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $55.01, for a total value of $160,189.12. Following the completion of the transaction, the insider now owns 4,456 shares in the company, valued at approximately $245,124.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Philip D. Gregory sold 2,931 shares of the company’s stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $39.52, for a total transaction of $115,833.12. Following the completion of the transaction, the insider now owns 30,069 shares of the company’s stock, valued at approximately $1,188,326.88. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bluebird Bio stock. State of Tennessee Treasury Department boosted its stake in Bluebird Bio Inc. (NASDAQ:BLUE) by 45.4% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 191,963 shares of the company’s stock after buying an additional 59,952 shares during the period. State of Tennessee Treasury Department owned approximately 0.52% of Bluebird Bio worth $12,328,000 at the end of the most recent quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.